BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection by preventing HA-mediated viral entry. The nanoparticles comprise icosahedral bacteriophage capsid proteins conjugated to mono-ethylene glycol-linked sialic acid, which...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...round announced in May 2019 (see “Creating A Portfolio With $150M” ). Targets HMHA1 (HA-1; HLA-HA1...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver vaccines....
BioCentury | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

...HA-1; HLA-HA1) - Histocompatibility minor HA-1 Elizabeth S. Eaton, Staff Writer ElevateBio LLC Histocompatibility minor HA-1 (HMHA1) (HA-1) (HLA-HA1) Major...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BioCentury | Aug 26, 2019
Product Development

Vax to the future: How Anthony Fauci is thinking about next-gen vaccines and other NIAID priorities

From his vantage point overseeing NIH’s infectious disease agenda, Anthony Fauci has identified vaccine development as an area poised to make big leaps. He says the institute’s prioritization of platform technologies holds more promise than...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
Items per page:
1 - 10 of 382